NASDAQ:DNLI

Denali Therapeutics (DNLI) Stock Price, News & Analysis

Denali Therapeutics logo
$18.08 -0.66 (-3.52%)
Closing price 04:00 PM Eastern
Extended Trading
$18.09 +0.01 (+0.06%)
As of 04:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Denali Therapeutics Stock (NASDAQ:DNLI)

Advanced

Key Stats

Today's Range
$18.08
▼
$18.86
50-Day Range
$17.61
▼
$22.28
52-Week Range
$15.34
▼
$27.30
Volume
1.15 million shs
Average Volume
1.72 million shs
Market Capitalization
$2.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.71
Consensus Rating
Moderate Buy

Company Overview

Denali Therapeutics is a biotechnology company focused on developing medicines for neurodegenerative diseases and other disorders involving the nervous system. Founded in 2015, the company is headquartered in South San Francisco, California.

Its research and development programs target conditions including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and lysosomal storage disorders. Denali’s portfolio includes investigational drug candidates that aim to address underlying disease processes, as well as its TransportVehicle platform, designed to help therapeutic molecules cross the blood-brain barrier.

Denali was co-founded by Ryan Watts, who serves as the company’s chief executive officer. Its medicines remain in development, and the company’s work includes research and clinical testing of potential treatments for patients with neurological conditions.

AI Generated. May Contain Errors.

Denali Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

DNLI MarketRank™: 
3.76442499005 of 5 stars

Denali Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 142nd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Denali Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 13 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Denali Therapeutics has a consensus price target of $35.71, representing about 95.0% upside from its current price of $18.32.

  • Amount of Analyst Coverage

    Denali Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Denali Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Denali Therapeutics are expected to grow in the coming year, from ($2.62) to ($2.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Denali Therapeutics is -10.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Denali Therapeutics is -10.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Denali Therapeutics has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    10.15% of the float of Denali Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Denali Therapeutics has a short interest ratio ("days to cover") of 9.91.
  • Change versus previous month

    Short interest in Denali Therapeutics has recently decreased by 5.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Denali Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Denali Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Denali Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 14 news articles for Denali Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    Only 2 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • MarketBeat Follows

    6 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,882.00 in company stock.

  • Percentage Held by Insiders

    9.70% of the stock of Denali Therapeutics is held by insiders.

  • Percentage Held by Institutions

    92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Denali Therapeutics' insider trading history.
Receive DNLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

DNLI Stock News Headlines

My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
Guggenheim reaffirms top pick in Biotech after Q3 results
See More Headlines

DNLI Stock Analysis - Frequently Asked Questions

Denali Therapeutics' stock was trading at $16.51 on January 1st, 2026. Since then, DNLI stock has increased by 10.9% and is now trading at $18.3160.

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings results on Tuesday, November, 3rd. The company reported $0.37 earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.64. The firm earned $17.78 million during the quarter, compared to analyst estimates of $12.67 million.
Read the conference call transcript
.

Denali Therapeutics (DNLI) raised $250 million in an initial public offering on Friday, December 8th 2017. The company issued 13,888,888 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Top institutional shareholders of Denali Therapeutics include State Street Corp (4.17%), Fisher Asset Management LLC (1.54%), Pictet Asset Management Holding SA (0.99%) and Aberdeen Group plc (0.95%). Insiders that own company stock include Ryan J Watts, Alexander O Schuth, Carole Ho, Vicki L Sato and Jennifer E Cook.
View institutional ownership trends
.

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), Intel (INTC), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Tesla (TSLA) and Boston Scientific (BSX).

Company Calendar

Last Earnings
11/03/2026
Today
11/16/2026
UBS Global Biopharma Conference 2026
11/17/2026
Jefferies Global Healthcare Conference
11/18/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DNLI
CIK
1714899
Fax
N/A
Employees
507
Year Founded
2015

Price Target and Rating

High Price Target
$42.00
Low Price Target
$24.00
Potential Upside/Downside
+97.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
17 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.73)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$512.54 million
Net Margins
N/A
Pretax Margin
-1,470.03%
Return on Equity
-54.94%
Return on Assets
-42.15%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
6.21
Quick Ratio
5.94

Sales & Book Value

Annual Sales
$330.53 million
Price / Sales
8.77
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.91 per share
Price / Book
2.62

Miscellaneous

Outstanding Shares
160,290,000
Free Float
144,743,000
Market Cap
$2.90 billion
Optionable
Optionable
Beta
1.08

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (NASDAQ:DNLI) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners